Nintedanib Teva (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby inhibiting the signals that drive fibroblast growth, migration and transformation into scar‑forming cells. This reduction in fibroblast activity limits the excessive deposition of extracellular matrix that characterises progressive lung fibrosis.

The specific dose and dosing schedule of Nintedanib are determined by the prescribing clinician based on the patient’s condition, renal and hepatic function, and concomitant therapies. Healthcare professionals should follow the approved prescribing information and adjust the regimen as clinically indicated.

Safety data for Nintedanib in pregnant or lactating women are limited, and the product is classified as contraindicated or not recommended during pregnancy. Women of child‑bearing potential should use effective contraception, and breastfeeding should be avoided unless the benefits outweigh potential risks as assessed by a physician.

To request Nintedanib Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative antifibrotic agent is pirfenidone, which also slows disease progression in idiopathic pulmonary fibrosis but has a different safety profile, notably a higher incidence of photosensitivity and rash. Nintedanib’s mechanism targets multiple tyrosine kinases, offering broader antifibrotic activity, while its most common adverse effect is gastrointestinal upset.

Nintedanib should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of direct sunlight and away from sources of humidity. Do not refrigerate or freeze the tablets, and retain them in a location inaccessible to children.

Nintedanib is taken orally, usually with food to lessen gastrointestinal discomfort. Patients should swallow the tablets whole with a full glass of water and follow the dosing instructions provided by their healthcare professional. Consistency in timing each day helps maintain stable drug levels.

Serious risks include liver enzyme elevations that may indicate hepatotoxicity, significant bleeding events, cardiovascular complications such as myocardial infarction, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should report persistent abdominal pain, unusual bruising, yellowing of the skin or eyes, and any severe rash to their physician promptly.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any of its excipients. It should also be avoided in individuals with severe hepatic impairment, uncontrolled bleeding disorders, or those who are pregnant. Clinicians must assess each patient’s medical history before initiating therapy.